Table 4

Effect of PTM202 on duration of diarrhoea among Guatemalan children by the presence of individual pathogen at urban site enrolment

PathogenInterventionnMedianHR95% CIP value*
hours
ETEC†PTM2021627.01.860.93 to 3.700.08
Placebo2135.8
STEC/0157†PTM20253.012.171.38 to 107.840.025
Placebo628.9
Rotavirus†PTM202620.11.380.41 to 4.670.60
Placebo641.5
Salmonella†PTM2021N/A2.450.15 to 39.720.53
Placebo341.9
Norovirus‡PTM2022624.61.660.94 to 2.940.08
Placebo2730.9
Shigella (EIEC)‡PTM2021425.62.520.88 to 7.230.09
Placebo741.1
CampylobacterPTM2021625.01.670.74 to 3.780.22
Placebo1139.8
Clostridium difficile PTM202522.66.431.17 to 35.290.03
Placebo730.9
PlesiomonasPTM2021N/AN/AN/AN/A
Placebo1N/A
Enteroaggregative Escherichia coli PTM2023325.61.150.71 to 1.890.57
Placebo3230.1
Enteropathogenic E. coli PTM2022725.61.630.94 to 2.830.08
Placebo2930.9
CryptosporidiumPTM202319.01.700.34 to 8.620.52
Placebo433.9
GiardiaPTM20275.22.270.47 to 11.040.31
Placebo317.2
AdenovirusPTM202823.41.530.52 to 4.500.44
Placebo765.7
Astrovirus*PTM202322.62.091.57 to 2.79<0.0001
Placebo346.3
SapovirusPTM202735.80.890.31 to 2.550.83
Placebo941.4
  • *HR not calculable due to bimodal distribution of the data; risk ratio using Poisson distribution is presented.

  • †Organism directly targeted by PTM202.

  • ‡Organism indirectly targeted by PTM202.

  • EIEC, enteroinvasive E.coli; ETEC, enterotoxigenic  E.coli.